首页> 外文期刊>The lancet oncology >Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial
【24h】

Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial

机译:pT3-pT4或N + M0膀胱尿路上皮癌的患者行根治性膀胱切除术后即刻化疗与延期化疗(EORTC 30994):一项跨组,开放标签,随机的3期试验

获取原文
获取原文并翻译 | 示例
           

摘要

Background Patients with muscle-invasive urothelial carcinoma of the bladder have poor survival after cystectomy. The EORTC 30994 trial aimed to compare immediate versus deferred cisplatin-based combination chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder.
机译:背景技术膀胱浸润性膀胱浸润性膀胱尿路上皮癌患者生存率较差。 EORTC 30994试验旨在比较pT3-pT4或N + M0膀胱尿路上皮癌患者根治性膀胱切除术后立即化疗与延迟顺铂联合化疗的疗效。

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号